These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 12057076)

  • 1. Epithelial ovarian cancer.
    Hensley ML
    Curr Treat Options Oncol; 2002 Apr; 3(2):131-41. PubMed ID: 12057076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Future directions in the chemotherapy of ovarian cancer.
    Ozols RF
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-86-S15-90. PubMed ID: 9346230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of gemcitabine-based doublets in the management of ovarian carcinoma.
    Thigpen T
    Semin Oncol; 2002 Feb; 29(1 Suppl 1):11-6. PubMed ID: 11840415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer.
    Tumolo S; Toffoli G; Saracchini S; Lo Re G; Bruschi G; Boccieri MG
    Lung Cancer; 2001 Dec; 34 Suppl 4():S37-46. PubMed ID: 11742701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer.
    Aravantinos G; Bafaloukos D; Fountzilas G; Christodoulou C; Papadimitriou C; Pavlidis N; Kalofonos HP; Gogas H; Kosmidis P; Dimopoulos MA
    Ann Oncol; 2003 Jul; 14(7):1094-9. PubMed ID: 12853352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chemotherapy for elderly patients with lung cancer].
    Okamoto H; Watanabe K
    Nihon Rinsho; 2002 May; 60 Suppl 5():591-5. PubMed ID: 12101743
    [No Abstract]   [Full Text] [Related]  

  • 8. [Gemcitabine].
    Takeda K
    Nihon Rinsho; 2002 May; 60 Suppl 5():359-65. PubMed ID: 12101689
    [No Abstract]   [Full Text] [Related]  

  • 9. Lung cancer: therapeutic options for stage IV and recurrent NSCLC.
    Calvo AR; Belani CP
    Cancer Treat Res; 2001; 105():189-227. PubMed ID: 11224988
    [No Abstract]   [Full Text] [Related]  

  • 10. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
    Edwards SJ; Barton S; Thurgar E; Trevor N
    Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine and vinorelbine in the second-line treatment of nonsmall cell lung carcinoma patients: a minnie pearl cancer research network phase II trial.
    Hainsworth JD; Burris HA; Litchy S; Erland JB; Hon JK; Brierre JE; Greco FA
    Cancer; 2000 Mar; 88(6):1353-8. PubMed ID: 10717616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent ovarian cancer metastatic to the sternum, costae, and thoracic wall after prolonged treatment with platinum-based chemotherapy: a case report and review of the literature.
    Pavlakis G; Mountzios G; Terpos E; Leivaditou A; Papadopoulos G; Papasavas P
    Int J Gynecol Cancer; 2006; 16 Suppl 1():299-303. PubMed ID: 16515608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic co-operative Oncology Group.
    Pectasides D; Kalofonos HP; Samantas E; Nicolaides C; Papacostas P; Onyenadum A; Visvikis A; Skarlos D; Fountzilas G
    Anticancer Res; 2001; 21(4B):3005-10. PubMed ID: 11712802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer.
    Kim SI; Lee EJ; Lee M; Chung H; Kim JW; Park NH; Song YS; Kim HS
    Int J Gynecol Cancer; 2020 Dec; 30(12):1943-1950. PubMed ID: 33055266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.
    Eng KH; Hanlon BM; Bradley WH; Szender JB
    Gynecol Oncol; 2015 Nov; 139(2):228-35. PubMed ID: 26383827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developmental chemotherapy and management of recurrent ovarian cancer.
    Bookman MA
    J Clin Oncol; 2003 May; 21(10 Suppl):149s-167s. PubMed ID: 17633784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Developed new agents for lung cancer].
    Kato Y; Saijo N
    Nihon Geka Gakkai Zasshi; 2002 Feb; 103(2):218-23. PubMed ID: 11904983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials.
    Pujol JL; Barlesi F; Daurès JP
    Lung Cancer; 2006 Mar; 51(3):335-45. PubMed ID: 16478643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-platinum combination of gemcitabine in NSCLC.
    Favaretto AG
    Ann Oncol; 2006 May; 17 Suppl 5():v82-5. PubMed ID: 16807471
    [No Abstract]   [Full Text] [Related]  

  • 20. [Updates on gemcitabine at the American Society of Clinical Oncology congress (ASCO, 2002) ].
    Gligorov J; André T; Epaud C; Culine S
    Bull Cancer; 2002 Aug; 89 Spec No():S134-44. PubMed ID: 12449045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.